Published in Cancer Res on June 01, 1993
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A (1996) 2.20
The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol (1994) 1.79
Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut (1998) 1.50
Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest (1997) 1.49
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther (2010) 1.46
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol (1995) 1.35
Urokinase and macrophages in tumour angiogenesis. Br J Cancer (1995) 1.19
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A (2003) 1.19
Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer (2000) 1.15
High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer (2009) 1.11
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer (1999) 1.05
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol (2003) 1.05
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res (2014) 1.02
Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ (1998) 1.01
Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. PPAR Res (2009) 1.01
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer (1998) 1.01
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer (1999) 0.98
Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor. Neoplasia (2009) 0.98
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer (1997) 0.98
Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer (1998) 0.96
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer (1997) 0.94
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest (1993) 0.94
MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice. PLoS One (2010) 0.93
Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia (2008) 0.91
Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer (1997) 0.90
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer (2005) 0.89
Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis (1998) 0.89
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer (1998) 0.86
Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis (1997) 0.85
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer (1999) 0.83
Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br J Cancer (1999) 0.83
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia (2007) 0.82
Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs (1997) 0.82
Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med (1999) 0.81
Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis (1998) 0.81
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas. Br J Cancer (1998) 0.81
Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer (1997) 0.81
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO2 pneumoperitoneum. Int J Colorectal Dis (2010) 0.79
Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br J Cancer (2003) 0.79
Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene (2016) 0.78
An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue. J Cancer (2014) 0.78
Synergistic Gene Expression Signature Observed in TK6 Cells upon Co-Exposure to UVC-Irradiation and Protein Kinase C-Activating Tumor Promoters. PLoS One (2015) 0.77
Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget (2015) 0.77
Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. Biochem Res Int (2014) 0.77
Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer (1996) 0.76
Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br J Cancer (1997) 0.75
Development of a Biomimetic Chondroitin Sulfate-modified Hydrogel to Enhance the Metastasis of Tumor Cells. Sci Rep (2016) 0.75
Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Res (2017) 0.75
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med (1997) 10.83
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet (1999) 8.44
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (1996) 2.88
Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ (2000) 2.80
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem (1991) 2.68
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem (1991) 2.61
Duodenal adenomatosis in familial adenomatous polyposis. Gut (2004) 2.38
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry (1983) 2.32
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Patient's and doctor's delay in primary breast cancer. Prognostic implications. Acta Oncol (1994) 2.27
[Improved prognosis of breast cancer]. Ugeskr Laeger (1994) 2.21
Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am (1997) 2.09
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone (2001) 2.00
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol (1988) 1.97
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol (1998) 1.95
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res (1995) 1.93
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol (1989) 1.93
Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr (1992) 1.93
[Surgical treatment of benign recurrent goiter. Technique, complications and permanent sequelae]. Ugeskr Laeger (1994) 1.92
Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol (1999) 1.86
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Risk of recurrence 5 years or more after primary Lichtenstein mesh and sutured inguinal hernia repair. Br J Surg (2007) 1.82
The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol (1994) 1.79
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol (1987) 1.79
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol (1993) 1.71
Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res (1992) 1.71
Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J (1999) 1.69
The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat (1994) 1.69
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer (2005) 1.68
A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry (1990) 1.68
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol (1988) 1.65
Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem (1998) 1.65
Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg (1985) 1.65
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg (2003) 1.61
Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab (1996) 1.61
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol (1987) 1.59
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol (2000) 1.58
Serum YKL-40 and colorectal cancer. Br J Cancer (1999) 1.57
Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry (1983) 1.56
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem (1992) 1.55
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol (1987) 1.53
Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res (1987) 1.53
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem (1991) 1.52
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem (1990) 1.52
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem (1986) 1.51
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene (1998) 1.51
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol (1991) 1.50
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem (1988) 1.49
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol (2000) 1.48
Lactational competence and involution of the mouse mammary gland require plasminogen. Development (2000) 1.48
Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res (1989) 1.48
Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group. Br J Surg (2000) 1.47
Diseases of the urachus simulating intra-abdominal disorders. Am J Surg (1971) 1.47
Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ (2000) 1.47
Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer (2002) 1.47
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem (1995) 1.45
A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem (2000) 1.44
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg (2002) 1.41
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol (1989) 1.41
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol (1984) 1.40
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res (2001) 1.40
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry (2001) 1.40
[Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen]. Ugeskr Laeger (1996) 1.38
[Surgical treatment of primary hyperparathyroidism]. Ugeskr Laeger (1997) 1.38
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
[Axillary dissection in primary surgical treatment of breast cancer: risk of false-negative axillary status]. Ugeskr Laeger (1992) 1.37
Strangulated diaphragmatic hernia. A clinical study. Am J Surg (1975) 1.37
The importance of surgery and accurate axillary staging for survival in breast cancer. Eur J Surg Oncol (1998) 1.37
Long-term storage of samples for flow cytometric DNA analysis. Cytometry (1983) 1.36
One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem (1988) 1.33
Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett (1991) 1.32
Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol (1988) 1.32
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res (2000) 1.31
92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer (1996) 1.30